Proteomic study revealed cellular assembly and lipid metabolism dysregulation in sepsis secondary to community-acquired pneumonia by Sharma, Narendra Kumar et al.
1Scientific RepoRts | 7: 15606  | DOI:10.1038/s41598-017-15755-1
www.nature.com/scientificreports
Proteomic study revealed cellular 
assembly and lipid metabolism 
dysregulation in sepsis secondary 
to community-acquired pneumonia
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Ramalho Ferreira  3, Ricardo Jose Soares Torquato2, Renato Arruda Mortara  3, Flavia 
Ribeiro Machado4, Murillo Assuncao5, Otelo Rigato1,6 & Reinaldo Salomao  1
Sepsis is a life-threatening disorder characterized by organ dysfunction and a major cause of mortality 
worldwide. The major challenge in studying sepsis is its diversity in such factors as age, source of 
infection and etiology. Recently, genomic and proteomic approaches have improved our understanding 
of its complex pathogenesis. In the present study, we use quantitative proteomics to evaluate the 
host proteome response in septic patients secondary to community-acquired pneumonia (CAP). 
Samples obtained at admission and after 7 days of follow-up were analyzed according to the outcomes 
of septic patients. The patients’ proteome profiles were compared with age- and gender-matched 
healthy volunteers. Bioinformatic analyses of differentially expressed proteins showed alteration in 
the cytoskeleton, cellular assembly, movement, lipid metabolism and immune responses in septic 
patients. Actin and gelsolin changes were assessed in mononuclear cells using immunofluorescence, 
and a higher expression of gelsolin and depletion of actin were observed in survivor patients. Regarding 
lipid metabolism, changes in cholesterol, HDL and apolipoproteins were confirmed using enzymatic 
colorimetric methods in plasma. Transcriptomic studies revealed a massive change in gene expression 
in sepsis. Our proteomic results stressed important changes in cellular structure and metabolism, which 
are possible targets for future interventions of sepsis.
Sepsis is a major cause of morbidity and mortality worldwide. The actual number of cases is unknown, as there 
is limited information from developing countries. An extrapolation from high-income country data suggests 
global estimates of 31.5 million sepsis and 19.4 million severe sepsis cases, with potentially 5.3 million deaths1. In 
a recent multicenter study in Brazil, one third of intensive care beds were occupied by septic patients, with a mor-
tality rate of 55.7%2. The place of acquisition, e.g., community-acquired or hospital-acquired infections, and the 
primary source of infection—respiratory tract, gastrointestinal tract, urinary tract, and surgical infections—are 
related to the etiology, pattern of microbial resistance and outcomes in sepsis3–5. Respiratory infection is a leading 
source of sepsis in ICU patients, accounting for more than 50% of infections5.
The concept of sepsis has been revised recently and is currently defined as life-threatening organ dysfunction 
caused by a dysregulated host response to infection6. Thus, sepsis results from a complex interaction between the 
host and the infecting microorganisms, in which the mechanisms of host defense are involved in the pathophys-
iology of the syndrome and play a major role in the outcomes7. Inflammatory and anti-inflammatory responses 
are triggered in sepsis, and the predominance of one response over the other during the ongoing infection may 
lead to the deleterious effects of inflammation or immunosuppression8,9. Inflammatory cytokines, such as tumor 
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necrosis factor-α (TNF-α), interleukin (IL)-1, and IL-6, lead to endothelial damage and activation of procoagula-
tion factors, which results in intravascular clotting, the formation of blood clots in small blood vessels, and mul-
tiple organ failure10. The inflammatory response leads to overwhelming oxidative stress, which results from the 
uncontrolled production of reactive oxygen species (ROS) and reactive nitrogen species (RNS)11. Mitochondrial 
enzymes are particularly vulnerable to oxidative stress, mainly to peroxynitrite, which leads to the cessation of 
electron transport and ATP formation, mitochondrial swelling, and permeabilization of the outer mitochondrial 
membrane12.
In recent years, proteomics has emerged as a powerful tool to evaluate the complex host-response to sepsis. 
This methodology is advantageous for the identification of biomarkers, altered pathways, functional alterations 
and mechanisms13,14. Several groups have investigated the proteome changes in animal models of sepsis as well 
as in septic patents13,15. Proteome studies have investigated the changes induced in human volunteers in response 
to lipopolysaccharides (LPS)16. Interestingly, circulating proteins, such as apolipoprotein, LDL, transferrin and 
holotransferrin, interact with the bacterial cell wall components - LPS and lipoteichoic acid (LTA) - and modulate 
their binding and the subsequent induced inflammatory response. Such proteins were found in lower abundance 
in non-surviving septic patients in one proteomic study17.
Few studies have been performed with septic patients, mostly without focusing on a primary source of infec-
tion18–20. One study evaluated proteome changes in patients with community-acquired pneumonia (CAP). The 
focus of the investigation was the alterations in the age-related pathways in young and old patients who could 
correlate with later development of sepsis21. In the present study, we evaluated the proteome changes in septic 
patients, focusing on changes related to immune and metabolic pathways in survivors and non-survivors. Aiming 
to avoid, at least in part, patient heterogeneity, we selected patients diagnosed with CAP as the source of infection. 
Samples were obtained at admission and after seven days of therapy to measure changes after the initial inter-
ventions. Using the absolute quantitative method iTRAQ, we were able to identify several differentially expressed 
proteins in septic patients compared to healthy volunteers and the associated outcomes. We used a bioinformatics 
tool to identify altered functions, pathways and regulatory networks. Our study provides evidence for a compro-
mised cytoskeleton, cell movement, the transport of macromolecules and energy metabolism in sepsis.
Results
A total of 425 septic patients were prospectively enrolled in the cohort, and 164 patients met the criteria for blood 
sampling. Of these 164 patients, 33 had CAP as the primary source of infection22 and were selected for this study, 
20 of whom survived and 13 of whom died during hospitalization (Fig. 1).
Figure 1. Schematic representation of a flow chart of a septic patient’s enrollment and selection Patients 
admitted to intensive care units with severe sepsis and/or septic shock were selected based on criteria of 
blood sampling, source and site of infection and their assigned group according to the final patient outcomes 
(survivors and non-survivors).
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Proteome changes. We have identified a total of 234 proteins with 1% FDR using the Swiss-prot database. 
After removing albumin and immunoglobulins and their isoforms from the identified proteins, we selected 179 
proteins for further analysis. Compared with healthy volunteers, we identified 64 differentially expressed pro-
teins in survivors at admission (D0) and 79 proteins in follow-up samples (D7). Similarly, we identified 68 and 
75 differentially expressed proteins in non-survivors at D0 and at D7, respectively (Supplementary Table S1). 
There were 48 proteins commonly differentially expressed, 16 proteins were specific to survivors, and 20 proteins 
were specific to non-survivors at day 0 (Fig. 2A). Similarly, 56 proteins were commonly differentially expressed, 
23 proteins were specific to survivors, and 19 proteins were specific to non-survivors after D7 (Fig. 2B). When 
protein changes were compared between D0 and D7 according to disease progression, 46 proteins were common 
in survivors at D0 and D7, while 18 and 33 proteins were specific to D0 or D7, respectively (Fig. 2C). Similarly, 46 
proteins were found in non-survivors at D0 and D7, while 22 and 29 proteins were specific to D0 or D7, respec-
tively (Fig. 2D).
Gene ontology annotations. Gene ontology annotation analysis enabled us to identify altered molecular function 
and biological processes (Supplementary Table S2). The top altered molecular functions that were identified in 
survivor and non-survivor groups at admission included cytoskeleton binding protein, motor activity, hemoglo-
bin binding, lipid binding and microtubule motor activity (Fig. 3A). There are several altered biological processes 
listed that are further categorized into three major subtypes. In the first category, we included cellular assembly 
and transport-related processes, where cytoskeleton organization, macromolecular complex subunit organiza-
tion, extracellular structure organization, microtubule-based movement, and protein/lipid/vesicle-mediated 
transport were observed in both groups. We found that maintenance of localization in the cell, cellular protein 
complex assembly, actin filament-based processes and regulation of transport were unique to survivors. Cell 
motility, localization of the cell and establishment of protein localization were found in non-survivors (Fig. 3B). 
In the second category, metabolism-related processes were included where lipoprotein/cholesterol/tryglyceride 
metabolic processes and the regulation of the fatty acid biosynthetic process were observed in both groups. The 
regulation of the lipoprotein/lipid metabolic process, single organism catabolic process and ATP catabolic process 
were observed in survivors, and hydrogen peroxide/retinoid catabolic processes were found in non-survivors 
(Fig. 3C). In the third category, we focused on immune response-related processes, such as homeostasis, blood 
coagulation, response to wounding, inflammatory response and acute-phase response, which were observed in 
both groups. Other processes, such as the defense response, regulation of body fluid levels and protein activation 
cascade, were altered in non-survivors (Fig. 3D).
At D7, we found more altered processes in the immune response, while other categories showed different 
responses between survivors and non-survivors (Supplementary Fig. S1). ATP binding, actin binding, spectrin 
binding, ankyrin binding and protein complex binding were observed in survivors, and haptoglobin binding, 
Figure 2. Venn diagram showing differential proteome expression between septic patient groups. The 
differential expression of proteins in survivors and non-survivors at admission (A) and D7 (B); the differential 
expression at D0 and D7 in survivors (C) and in non-survivors (D). The Venn diagram was created using the 
online tool Venny 2.1. http://bioinfogp.cnb.csic.es/tools/venny/index.html).
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antioxidant activity, calcium ion binding and endopeptidase regulator activity were observed in non-survivors 
after 7 days.
Functional analysis with ingenuity pathway analysis. Several biological processes were identified and categorized 
on the basis of their IPA score. Metabolic disease, lipid metabolism, small molecule biochemistry and cellular 
assembly and organization were identified with the highest IPA scores in all groups; however, specific molecules 
have different expression values in different groups (Supplementary Table S3). There are several key molecules 
that hold the central node, such as CRP, LBP and HDL, and interact with several other differentially expressed 
proteins, such as the family of apolipoproteins (S) (Supplementary Fig. S2).
Functional analysis demonstrated activation or inhibition of functions based on z-scores (Supplementary 
Table S4). We found that the uptake of lipids, engulfment of cells, coagulation and phagocytosis of cells were acti-
vated; however, fatty acid metabolism, export of molecules, transport of lipid and phospholipids, cell movement 
of phagocytes and metabolism of reactive oxygen species (ROS) were inhibited in survivors and non-survivors 
after admission. We also found that some functions were outcome-specific. Microtubule dynamics, organization 
of the cytoskeleton, phagocytosis and quantity of filaments were activated, and bleeding and adhesion of immune 
cells were inhibited in survivors (Fig. 4A). Activation of macrophages and synthesis and production of ROS 
were inhibited in non-survivors (Fig. 4B). Interestingly, we identified cell movement and inflammatory response 
inhibition in survivors, while activation was observed in non-survivors; this pattern was inversed at D7. In D7 
samples, migration of cells, transport of molecules and adhesion of immune cells were activated, and synthesis, 
production and metabolism of ROS, bleeding, transport of lipid and export of molecules, and thrombosis were 
Figure 3. Gene ontology annotation for molecular function and biological processes for differentially expressed 
proteins. Altered molecular functions between septic survivors and non-survivors at admission are shown in 
(A). Biological processes were further categorized accordingly as follows: associated cellular organization and 
movement (B); alteration associated with metabolism (C); and immune response-related altered processes (D). 
The molecular functions and biological processes are shown at the corresponding P-value ≤ 0.01 with FDR B&Y 
multiple corrections.
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inhibited in survivors (Fig. 4C). Similarly, engulfment of cells, thrombosis, infarction and phagocytosis were 
activated, and the quantity of actin filaments, activation of macrophages and phagocytes and cell movement of 
phagocytes were inhibited in non-survivors (Fig. 4D).
Canonical pathway analysis. Canonical pathway analysis identified altered pathways and top-listed pathways 
with significant P-values and included LXR/RXR activation, acute-phase activation, FXR/RXR activation, inter-
leukin signaling, coagulation, intrinsic and extrinsic prothrombin activation pathway and actin cytoskeleton 
signaling in both groups; however, the number of proteins, P-values and expression values were different in sur-
vivors and non-survivors (Fig. 5 and Supplementary Table S5).
Proteins related to altered biological functions. Proteins related to organization of the cytoskeleton and 
microtubule dynamics. We have identified several differentially expressed proteins that are responsible for differ-
ent functions in the living system. Several proteins representing cellular assembly were found to be altered in all 
groups, such as KIF27, NF1, MYH9, MYO5B, ALMS1, SYNE1, ASPN (upregulated) and GSN, PLEC, PON1, F2, 
GCC2 (downregulated). Some proteins of a dynein heavy chain family member, a microtubule-dependent motor 
ATPase, have been identified after admission, including DNAH5, DNAH8, DNAH10, DNAH11 and DNAH12 
(upregulated); DNAH5, DNAH10, and DNAH11 were identified in survivor follow-up groups. We identified 
some proteins in survivors at D0 and D7, such as OBSCN, TTN (upregulated) and SPTBN4 (downregulated), 
Figure 4. Functional analysis curated by Ingenuity Pathway Analyses. Interaction between altered functions 
and their association with proteins are represented based on their Z-score in the functional network. (A) Refers 
to the functional alteration in survivors; (B) Refers to non-survivors at admission; (C) Refers to D7 survivors; 
and (D) refers to D7 non-survivors.
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while SYNE2 (downregulated) was identified in non-survivors at D0 and D7. NUMA1 and SPTAN1 (downreg-
ulated) were identified after admission and in the survivors group after day 7. Importantly, we also identified 
changes in several proteins such as ACTA1, ACTB, MYH13, MYO5A, MY07A and MYO9A in the different 
groups (Supplementary Table S1).
Figure 5. IPA canonical pathway analysis in septic patients. (A) Refers to altered canonical pathway in 
survivors; (B) refers to non-survivors at admission; (C) refers to survivors; and (D) refers to non-survivors 
after D7. Enriched canonical pathways were identified from the IPA library using Fisher’s exact test adjusted for 
multiple hypothesis testing using the Benjamini- Hochberg correction.
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Proteins related to cell movement. Cell migration is a central process in the immune response or the pathogen 
entry; impairment of this function has serious consequences. Apart from some proteins included in the cytoskele-
ton, we identified several other proteins, including HEXIM1, LAMA3, FGA, FGB, ATM, DNAH11, SERPINEA3, 
SAA1, HP, CRP, LBP (upregulated) and SERPINAD1 and KLKB1 (downregulated). ORM1 protein was upregu-
lated after admission and downregulated in follow-up samples. Some of these proteins, such as SAA1, HP, CRP 
and LBP, were included in the acute-phase proteins (Supplementary Table S1).
Proteins related to energy metabolism. Energy metabolism is the process of generating ATP and is essential in 
maintaining homeostasis and various signaling in the cell. Dysregulation in energy metabolism leads to the altera-
tion of various cellular functions and signaling. We identified downregulated apolipoprotein family proteins, such 
as APOA1, APOA2, APOA4, APOB, APOC1, APOC2, APOC3, and APOE in septic patients. Apolipoprotein 
members APOD and APOE were downregulated after admission. Some of these proteins are responsible for the 
uptake of lipids and the transport of phospholipids. Apolipoproteins with PON1, GSN, SAA1, LBP, MYO5A, and 
F2 are responsible for alterations in fatty acid metabolism, and with the addition of SERPINA1 and SERPINA3, 
altered reactive oxygen species metabolism (Supplementary Table S1).
Proteins related to inflammation, coagulation and bleeding. Inflammation is a complex biological response 
against pathogens. In the present study, we identified several inflammatory response-related proteins, including 
HP, FGG, ATM, SERPINA1, SERPINA3, CRP and LBP (upregulated) and F2, GSN and PON1 (downregulated). 
Some of these proteins are also key molecules in coagulation and bleeding.
Validation results. Confocal analysis for actin and gelsolin. Proteomic data have provided evidence for a 
higher expression of actin (main component of the cytoskeleton) in plasma. To confirm the proteomic data, we 
compared actin in the PBMCs and PMNs from septic patients to that of healthy volunteers. We found a decreased 
expression of actin in the septic patient’s blood mononuclear cells, with acute depletion in the non-survivors. 
In contrast, gelsolin had a higher expression in survivor septic patients than in non-survivor septic patients 
(Fig. 6A). Changes in the PMNs showed a different pattern; gelsolin was decreased in septic patients, and actin 
was decreased only in the non-survivor groups (Fig. 6B).
Lipid and lipoprotein analyses. Our proteomic data showed alterations in lipid metabolism and dysregulation of 
apolipoproteins. For further confirmation, we estimated the level of total cholesterol, HDL-C, LDL-C, triglycer-
ides, ApoA-I, Apo B and lipoproteins. We found that the level of total cholesterol was significantly decreased in 
septic patients, and no significant differences were observed between survivor and non-survivor septic patients 
(Fig. 7A). The HDL-C levels decreased significantly in septic patients, and increased levels have been observed 
in survivors at D7 compared to D0. In contrast, no significant differences were observed in non-survivor septic 
patients in the follow-up samples (Fig. 7B). LDL-C and HDL free cholesterol levels were also decreased in septic 
patients, whereas survivors showed significant changes at admission (Fig. 7C and D). No significant differences 
were observed in triglyceride levels in septic patients (Fig. 7E).
Apo A-I is the major protein of HDL composition. We found significantly decreased levels in septic patients in 
a similar pattern as HDL-C (Fig. 7F). Apo B protein was significantly decreased only in survivors at D0, while no 
significant differences were observed in lipoprotein levels (Fig. 7G and H).
Discussion
Sepsis is a syndrome resulting from various sources of infection that lead to changes in the inflammatory response 
and cellular metabolism, ultimately resulting in organ dysfunction and death23. We aimed to evaluate these 
changes at the protein level and selected those patients with CAP to avoid the heterogeneity of sepsis secondary 
to multiple sources of infection, the impact of underlying diseases and previous interventions of patients with 
hospital-acquired infections.
Overall, the number of proteins identified was similar in the different groups of septic patients, and spe-
cific changes were observed for survivors and non-survivors as well as for admission and follow-up samples. 
Gene ontology results pointed to major changes in the cytoskeleton and cell movement, energy metabolism and 
immune response-related processes. These changes were further supported by IPA analyses showing that the top 
altered functions included cellular assembly and organization, the actin-cytoskeleton pathway, metabolic disease, 
lipid metabolism and acute-phase response signaling.
Our current findings corroborated with the meta-analysis of transcriptomic data showing the cytoskeleton as 
a top altered pathway in septic patients24. We found several proteins related to the organization of the cytoskele-
ton and microtubule dynamics that were altered in our patients. Importantly, actin, gelsolin and myosin, major 
components of the cytoskeleton, were altered in septic patients; actin levels were increased, and levels of gelsolin 
were decreased in plasma. Interestingly, immunofluorescence analyses showed a decreased expression of actin 
in mononuclear cells of septic patients that was more pronounced in non-survivors than in survivors. Actin was 
also decreased in polymorphonuclear cells (PMNs), with a greater magnitude in non-survivors than in survivors. 
Gelsolin presented with a different pattern in mononuclear cells and PMNs, with increased expression in mono-
nuclear cells in survivors and decreased expression in PMNs in the entire cohort of septic patients.
Actin is a conserved essential multifunctional protein and structural unit of the cytoskeleton of the cell. 
Dysregulation of actin resulted in the alteration of various cellular processes, transport of molecules, signal-
ing pathways, cell migration and wound repair. We found an altered actin cytoskeleton pathway, which sup-
ported previous proteomic results in septic patients21. Lee et al. showed circulating actin in the plasma of septic 
patients25, which increased blood viscosity, obstructing small blood vessels26,27 and enhancing the bacterial infec-
tions under activation of purinergic receptors through binding to adenine nucleotides and the production of 
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alpha hemolysine28. The dead cells supposedly are the source of free actin in plasma; however, our results sug-
gested that circulating blood cells can also be a source of free actin.
Gelsolin is an actin-binding cytoplasmic and circulating protein, which effectively scavenges actin filaments in 
blood plasma27. It also binds to pro-inflammatory and bioactive mediators to localize inflammation, bacterial sur-
face lipopolysaccharides, and inactivates bioactive lipid mediators such as lysophosphatidic acid, Gram-negative 
bacteria lipopolysaccharide, and platelet-activating factor29,30. Plasma gelsolin levels are significantly decreased 
in major trauma, burns, surgery and sepsis, whereas recovery of circulating gelsolin has been correlated with 
improvement in patient outcomes. Recombinant gelsolin administration showed a reduction in mortality in 
experimental sepsis31–33. Thus, our proteomic results showing increased levels of actin and decreased levels of 
gelsolin in plasma are consistent with previous reports and stress important changes in the cytoskeleton during 
sepsis. A higher expression of gelsolin and lower expression of actin were detected in mononuclear cells from 
survivor patients, which suggests that gelsolin nucleates actin monomers in filaments for maintaining the actin 
cytoskeleton. In contrast, a lower expression of actin and gelsolin found in septic non-survivors may make mon-
onuclear cells more vulnerable, hence resulting in alterations in cellular assembly and maintenance. Recently, the 
ratio of actin to gelsolin in plasma was suggested as a biomarker for sepsis34.
Our proteomic results showed downregulation of apolipoproteins, such as ApoA2, ApoA4, ApoC1, ApoC2, 
ApoC3, Apod and Pon1, and upregulation of acute-phase proteins, such as SAA, HP, HPR and LBP, in the plasma 
of septic patients. Hence, lipids and lipoproteins were further evaluated in plasma to support our proteomic find-
ings. Accordingly, we found lower levels of total cholesterol, HDL-C and APO A-I in the plasma of septic patients 
compared to healthy volunteers using enzymatic, colorimetric and immunoturbidimetric methods.
Septic patients have been reported to present low levels of total cholesterol35 and high-density lipoprotein 
(HDL)36. de la Llera et al. have described the alteration of HDL composition and function with increased expres-
sion of SAA, decreased expression of phospholipids, apoA-I, lipid-poor pre-β1 and small-medium-sized par-
ticles in response to human endotoxemia37. Recently, Cirstea et al. demonstrated decreased HDL-C levels as a 
Figure 6. Confocal microscopy for actin and gelsolin in circulating blood cells. (A) Refers to cellular expression 
for actin and gelsolin with nuclear staining in peripheral blood mononuclear cells (PBMCs) of healthy 
volunteers (n = 10), septic survivors (n = 13 at D0 and n = 9 at D7) and non- survivors (n = 10, at admission and 
after D7). Similarly, (B) refers to cellular expression for actin and gelsolin in polymorphonuclear cells (PMNs) 
in healthy volunteers (n = 9), septic survivors (n = 6 at D0 and n = 11 at D7) and non-survivors (n = 11 at D0 
and at D7). Data are represented as the geographic means of cell fluorescence analyzed using ImageJ software 
(National Institutes of Health, Bethesda, MD, USA) for actin and gelsolin. *Denotes P ≤ 0.05 when compared to 
control, #Denotes when compared to septic survival at admission.
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prognostic marker for early organ failure and death in septic patients. The study suggested that the decreased 
levels of HDL-C are unchanged for 7–10 days in hospitalized septic patients38. Interestingly, our current find-
ing demonstrated a similar pattern in non-survivors, while septic survivors showed an increased expression in 
follow-up samples compared to samples at admission.
Apolipoproteins transport cholesterol to other cells and tissues; hence, downregulation resulted in an alter-
ation of cholesterol transport. Guo et al. demonstrated decreased LPS neutralization in apoAI knockout mice 
lacking HDL39. Low levels of HDL-C and apoA-1 in severe septic patient plasma is associated with increased 
mortality40. In contrast, higher levels of apoA-I improve survival41 and reduce TNF-α levels in response to LPS 
in rodents42. These studies support a role for apoA-1 in inhibiting the inflammatory cytokine production in sep-
sis35. Septic patients showed displacements of apoA-I with SAA; hence, SAA became the major component of 
HDL36,43. Our results showed increased SAA and decreased Apo A, which further supports these changes in the 
HDL components.
Changes in lipid moieties revealed the inhibition of LXR/RXR activation as the most altered pathway using 
IPA in our cohort of septic patients. These results corroborate with the results from a previous study in CAP 
patients, which also found LXR/RXR as the most altered pathway21. This pathway is involved in the regulation 
of lipid metabolism, inflammation, and cholesterol-to-bile acid catabolism; hence, it resulted in the alteration of 
lipid metabolism in patients.
Our proteomic data suggested counter-regulatory action to the excess of production, synthesis and metab-
olism of ROS in septic patients through increased expression of acute-phase response proteins. We have previ-
ously shown that monocytes and neutrophils from septic patients have an increased capacity to generate NO and 
ROS44,45. Mitochondria are a source and target of ROS in sepsis. In our previous transcriptomics study involving 
septic patients with CAP that belong to this same cohort, we observed differences in the expression profile of 
genes related to the mitochondrial electron transport chain (ETC) I-V between survivors and non-survivors at 
the time of patient admission46. Furthermore, using a PCR-array encompassing genes belonging to the inter-
acting TLR cascades, NADPH-oxidase and mitochondrial oxidative phosphorylation, we found that the redox 
imbalance (iNOS signaling, oxidative phosphorylation and superoxide radical degradation) affecting mitochon-
drial functions was prominent in non-surviving septic patients47. The present proteomic data also suggested the 
activation of phagocytosis, engulfment and phagocytosis of cells in septic patients. This is in contrast with the 
current concept showing hyporesponsiveness of innate immune cells in sepsis48; however, it is in agreement with 
experimental data showing that bone marrow-derived mice macrophages and human monocytes made tolerant 
to TLR agonists presented with increased phagocytosis and respiratory burst49,50. Further support is provided by 
our previous results showing that monocytes of septic patients presenting with a decreased production of inflam-
matory cytokines showed an increased level of RONS and preserved phagocytosis51.
Finally, we found inflammatory and immune response-related processes as well as activation of coagulation 
and the intrinsic and extrinsic prothrombin activation pathway in sepsis, supporting data from transcriptomics 
and proteomic studies13,52,53.
Figure 7. Estimation of lipid moieties in blood plasma. (A) Refers to total cholesterol; (B) refers to HDL-C; (C) 
refers to LDL-C; (D) refers to HDL free cholesterol; (E) refers to triglyceride levels; F refers to apo A-I; (G) refers 
to Apo B; and (H) refers to lipoprotein fraction levels in healthy volunteers, septic survivors and non-survivors. 
The results are presented as box plots and analyzed using one-way ANOVA with Tukey’s post hoc multiple 
comparison test, where P ≤ 0.05 is considered significant. *Denotes P ≤ 0.05 when compared to control, 
#Denotes when compared to septic survival at D0.
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Previous proteomic studies revealed a wide range of altered pathways in sepsis. Our data add important new 
insights to the previously described studies and confirmed some previous findings. The cytoskeleton alteration, 
previously demonstrated by the detection of few circulating proteins such as actin and gelsolin, could be doc-
umented by a number of proteins involved in cytoskeleton assembly and cellular organization. As a result, this 
pathway emerged as one of the most altered in gene ontology and functional analyses. Furthermore, our results 
showed metabolic disease, lipid metabolism and small molecule biochemistry as the top altered functions in sep-
tic patients and identified HDL and lipid moieties as important components in the interaction network. Thus, our 
proteomic results stressed the important changes in cellular structure and metabolism, which could be possible 
targets for future interventions of sepsis.
Our study has some strengths and limitations. Patients were selected from a multicenter sepsis cohort, and 
heterogeneity was partially circumvented by selecting patients with a single source of community-acquired infec-
tion. The number of proteins identified in our study is in the range of those reported in the literature, despite a 
few studies that identified more proteins than our study. Moreover, selecting septic patients with CAP restricted 
the number of patients with preserved plasma samples. Despite validating proteomic results using an immuno-
fluorescence cellular assay and the plasma determination of lipid moieties, several cell functions showing alter-
ations at the protein level were not evaluated in in vitro experiments. Nevertheless, most of the altered pathways 
were consistent with previous genomic and proteomic results as well as with described cellular changes in septic 
patients.
Methods
Patients, sample collection and processing. A cohort of septic patients was enrolled from the Intensive 
Care Units of three general hospitals located in São Paulo, Brazil. This study followed the guidelines of the 
Declaration of Helsinki for research on human participants and was approved by the ethics committees of the par-
ticipating hospitals, São Paulo Hospital (Study number 1477/06), Albert Einstein Hospital (Study number 07/549) 
and Sírio-Libanês Hospital (Study number 2006/27). Informed consent was obtained from all participants or 
relatives before enrollment. Patients were enrolled within 48 hours of the first occurrence of organ dysfunction 
indicative of severe sepsis or septic shock. Exclusion criteria included patients receiving immunosuppressive 
therapy, and patients diagnosed with AIDS, end-stage chronic illness, or who had been submitted to experimental 
therapy. Patients with CAP as the primary source of infection, older than 40 years of age, were selected for the 
study. Twenty-three healthy volunteers matched for age- and gender were included as the control group (Table 1).
Blood samples from septic patients were collected at admission (D0) and after seven days (D7). Peripheral 
blood mononuclear cells (PBMC) and polymorphonuclear cells (PMN) were obtained using the Ficoll-Paque 
PLUS (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and Dextran 3% (Amresco, Solon, Ohio, USA), respec-
tively. Cells were stored in liquid nitrogen until use.
Depletion of plasma. Highly abundant proteins such as albumin and immunoglobulin were depleted using 
a proteome minor kit (BioRad, California, USA).
Digestion. After determining the protein concentration using the Bradford assay, aliquots of up to 100 μg 
of protein were placed into separate tubes, and the sample volumes were equalized using 1 M TEAB. Cysteine 
disulfide bonds were reduced with 0.1 volumes of 50 mM TCEP, and samples were mixed on a vortex, quick spun 
Control (N = 23) Sepsis (N = 33) Survival (20) Non-survival (13)
Age 64.95 ± 14.56 68.33 ± 15.84 63.75 ± 16.99 75.38 ± 11.12
Sex 60% male 66.6% male 60% male 76.92% male
Septic Shock NA 81.10% 75% 92.30%
Apache II NA 20.21 ± 5.95 20.01 ± 6.61 20.38 ± 5.0
SOFA NA 8.12 ± 3.06 8.25 ± 3.5 7.92 ± 2.36
SOFA Delta (day3-day0) NA (−)0.5 ± 4.26 (−)2.5 ± 2.7 2.23 ± 4.54
Organ Dysfunction
 Cardiovascular NA 87.80% 85.00% 92.30%
 Renal NA 45.40% 55% 30.76%
 Respiration NA 69.7 70% 69.23
 Hematological NA 18.18% 15% 23.07%
 Hepatological NA 15.15% 10% 23.07%
 Nervous system NA 42.42% 35% 53.84%
Underlying Diseases
Corticosteroids NA 42.42% 45% 38.46%
AIDS NA 0 0 0
COPD NA 27.27% 30% 23.07%
Immunosuppression NA 9.09% 10% 7.69%
Table 1. Clinical variables and demographic data from septic patients. All values are presented as the 
means ± SD. SOFA, Sequential Organ Dysfunction Assessment; COPD, Chronic Obstructive Pulmonary 
Disease; N/A, not applicable.
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and incubated at 60 °C for 1 h. Reduced cysteine residues were alkylated by adding 0.05 volumes of 200 mM meth-
ylmethanethiosulfate. Samples were mixed on a vortex, quick spun and incubated at room temperature (RT) for 
10 min. To each tube, 10 μg of trypsin was added, which had been reconstituted in the supplied buffer and diluted 
in 20 μl of 1 M TEAB, mixed on a vortex, quick spun and incubated at 37 °C overnight.
iTRAQ labeling. The sample volume was reduced using a SpeedVac at RT, and the volume was adjusted back 
to 30 μl using 1 M TEAB. The required iTRAQ reagents were removed from the freezer, and the reagent vials 
were quick spun. A total of 60 μl of isopropanol was added to each reagent vial, mixed and quick spun. The entire 
contents of the reagent were transferred to appropriate sample tubes, well-mixed and incubated at RT for 2 h. The 
volume was reduced to ~30 μl on a SpeedVac at RT to prevent the sample from drying out.
Sample fractionation using SCX chromatography. A total of 100 μl of SCX-A buffer was added to 
each sample tube, and all tubes were pooled in a single vial. The pH was adjusted to <2.7 using 1 M hydrochloric 
acid. The entire sample was transferred to a glass sample vial, and the volume was adjusted to 1.6 ml with SCX-A. 
After this, the sample was loaded onto the analytical column using a 2-ml injection loop and was washed with 
100% SCX-A at the rate of one ml per minute for 30 min. The peptide mixtures were separated using a gradient 
that increased from 0 to 15% SCX-B over 35 min, 15 to 30% SCX-B in 5 min and 30 to 100% SCX-B in 5 min at a 
flow rate of 400 μl per minute. Fractions of peptides were collected into 1.5-ml tubes after each minute. Typically, 
40 fractions were collected from 5 min to 45 min after the start of the gradient. Peptide fractions were dried to 
~20 μl. After the separation of peptides, 100% SCX-B was run for 15 min to wash the column and re-equilibrated 
at 100% SCX-A for a final 15 min.
LC-MS/MS analysis. LC-MS/MS analysis of iTRAQ-labeled peptides was performed on a Synapt G2 mass 
spectrometer interfaced with a nanoacquity UPLC nanoflow liquid chromatography system (Waters, Miliford, 
MA, USA). The fractions were enriched on a trap column (180 µm × 2 cm, 5 µm, Waters, Miliford, MA, USA) 
at a flow rate of 8 µl/min for 5 min and then resolved on an analytical column (75 µm × 15 cm, 1.7 µm, Waters, 
Miliford, MA, USA) with the application of a voltage of 3Kv. The peptides were eluted using a linear gradient 
of 7–30% solvent B (90% acetonitrile in 0.1% formic acid). LC-MS/MS data were acquired using positive ion 
mode in a data-dependent manner from m/z 300 to 1600Da, targeting the three most abundant ions in the 
survey scan. MS data were acquired in the QTOF analyzer, and MS/MS spectra were acquired for 1.5 seconds. 
Collision-induced dissociation mode (CID) was used for MS/MS scans.
Mass spectrometry data analysis. The individual raw files were processed with Mascot Distiller (Matrix 
Science, USA) and all files were merged using Mascot Daemon software. The merged processed data were 
searched against a reviewed UniProt database containing human proteins with known contaminants (20,120 
entries). The parameters used for data analysis including trypsin as a protease (allowed one missed cleavage), 
iTRAQ label at N-terminus and lysine residues, and cysteine modification by methyl methanethiosulfonate 
(MMTS) were specified as fixed modifications. Oxidation of methionine was specified as a variable modification. 
The precursor and product ion mass error tolerance were fixed at 20ppm and 0.1 Da, respectively. The peptide and 
protein data were extracted using high peptide confidence (P ≤ 0.05), and a minimum of 2 peptides were used 
for protein identification. The false discovery rate (FDR) was calculated using decoy database searches. Peptides 
identified at 1% FDR were used for protein identification. The results from Mascot Server were loaded in isobar-
icQ for iTRAQ quantitation.
Bioinformatic analysis of proteomics data. To understand the functions and signaling that are affected 
during sepsis, we converted the protein list to gene names and analyzed them with ToppGene Suite and Ingenuity 
Pathway Analysis (IPA) (Qiagen bioinformatics, CA, USA). For gene ontology annotations, a differentially 
expressed gene list was uploaded in the section of ToppFun of ToppGene Suite with FDR B&Y correction with a 
P-value cut-off at 0.05 (https://toppgene.cchmc.org/enrichment.jsp). For IPA analysis, the gene list was uploaded 
in the IPA module and the fold change cut-off was set at ±1.3 for further functional, pathway and regulatory 
network analysis.
Confocal microscopy. After thawed, PBMCs and PMNs were spun on glass slides (poly-lysine treated; 
0.05%), fixed with 4.0% paraformaldehyde in PBS for 15 min at RT, washed with PBS, and then incubated with 
blocking solution PGS (0.2% gelatin, 0.1% saponin and 0.1% NaN3, diluted in PBS) for 1 h at RT. The cells were 
incubated overnight with the primary antibody, mouse anti-Gelsolin (1:100 diluted in PGS, Sigma-Aldrich, 
St. Louis, MO, USA). After washing with PBS, they were incubated with green fluorescent Alexa Fluor 488 
anti-mouse (1:150), phalloidin-TRITC (1:1000 diluted in PGS, Sigma-Aldrich, St. Louis, MO, USA) for actin, 
and the nuclear material was stained with 4, 6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). Cells were then 
washed with PBS and mounted in glycerol buffered with 0.1 M Tris, pH 8.6, with 0.1% p-phenylenediamine as an 
anti-fade agent. Images of stained cells were acquired with a TCS SP5 II Tandem Scanner confocal microscope 
(Leica Microsystems, Wetzlar, Germany) using a 63x NA 1.44 PlanApo oil immersion objective and processed 
with Imaris® (Bitplane). The images were further analyzed in the program ImageJ (National Institutes of Health, 
Bethesda, Maryland, USA) using the measuring of cell fluorescence as described earlier54 and were quantified 
from the average correspondence of two to four cells/randomly selected field.
Biochemical assays. To validate the proteomics data, we determined plasma levels of cholesterol and lipids 
moieties using biochemical assays (COBAS 6000 automated system, C501 Japan). All reagents were obtained 
from Roche (USA).
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Statistical analysis. For gene ontology, the probability density function was selected and the P-value cut-off 
was set at 0.01 using the FDR B&Y multiple correction method. Enriched canonical pathways were identified from 
the IPA library using Fisher’s exact test and adjusted for multiple hypothesis testing using the Benjamini-Hochberg 
correction. For functional activation and inhibition, Z-statistics were used where the value of Z ≥ 2.0 refers to 
predicted activation and Z ≥ −2.0 refers to predicted inhibition for particular functions. For the protein-protein 
functional interaction network, a 0.05-FDR threshold cut-off was set to identify genes corresponding to identified 
proteins whose expression was significantly differentially regulated. These genes, called focus genes, were overlaid 
onto a global molecular network developed from information contained in the database. Networks of these focus 
genes were then algorithmically generated based on their connectivity and assigned a score. Statistical analysis was 
performed using GraphPad Prism 6 (GraphPad Software, Inc., USA) for confocal and enzymatic colorimetric anal-
yses. For confocal analyses, data were represented as the geometric means of cell fluorescence for actin and gelsolin 
and analyzed using one-way ANOVA followed by Tukeys’ multiple comparison test where P ≤ 0.05 was considered 
significant. For total cholesterol, HDL-C, LDL-C, HDL free cholesterol, triglycerides, Apo A-I, Apo B and lipo-
proteins, data were represented in box plots and analyzed using one-way ANOVA, and Tukey’s post hoc multiple 
comparison test was used where P ≤ 0.05 was considered significant Table 1.
Data availability. Most of data generated or analysed during this study are included in this published article 
(and its Supplementary Information files). Any further information is available from the corresponding author 
on reasonable request.
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